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In this review, state-of-the-art evidence on the relationship between cannabis use, traffic
crash risks, and driving safety were analyzed. Systematic reviews, meta-analyses, and
other relevant papers published within the last decade were systematically searched
and synthesized. Findings show that meta-analyses and culpability studies consistently
indicate a slightly but significantly increased risk of crashes after acute cannabis use.
These risks vary across included study type, crash severity, and method of substance
application and measurement. Some studies show a significant correlation between
high THC blood concentrations and car crash risk. Most studies do not support
this relationship at lower THC concentrations. However, no scientifically supported
clear cut-off concentration can be derived from these results. Further research is
needed to determine dose-response effects on driving skills combined with measures
of neuropsychological functioning related to driving skills and crash risk.
Keywords: cannabis, cannabinoids, THC, automobile driving, impaired driving, driving safety, driving skills, driving
ability

INTRODUCTION
Cannabis is worldwide the most frequently used illicit drug (1). Rates of driving under the influence
of cannabis rose in recent years (2). For instance, the DRUID (Driving Under the Influence of
Drugs, Alcohol and Medicines) project reported on 50,000 drivers from 13 different countries of
whom 1.32% used cannabis (3). On weekends, the rates of positively screened cannabis users in
traffic were 10–12% and in subjects involved in a car crash 26–27% (3, 4), while 0.5–7.6% of persons
involved were severely injured.
“Cannabis-impaired driving” describes the impairment caused by cognitive and psychomotor
effects of 19-tetrahydrocannabinol (THC) which negatively influences a driver of a motor vehicle
after THC consumption. In contrast, a “cannabis-positive driver” is someone driving a motor
vehicle with any detectable THC concentration in blood, oral fluid, or urine with/without showing
impairments in his driving. “Driving under the influence of cannabis” (DUIC) is a judicial term
which refers to a driver exhibiting a measured reduction in cognitive or psychomotor skills in
conjunction with a defined THC concentration in blood, oral fluid, or urine (5).
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THC acutely and probably chronically reduces different
cognitive and psychomotor abilities needed for driving, like
balance, executive function, motor impulsivity and impulse
control, perception, psychomotor speed, short-term memory,
visual processing, and working memory (reaction time and
accuracy) (3, 6). All these reductions may be dose-dependent
(4), negatively influence driving skills and car crash risk,
and may worsen with duration and frequency of cannabis
use (5). However, results on the relationship between driving
performance and traffic crash risk under the influence of cannabis
revealed inconsistent findings (6–8).
Methodological heterogeneity may explain mixed findings. As
summarized by Asbridge et al. (2), several study types need to
be considered for a comprehensive evaluation of the relationship
between cannabis use, driving skills, and car crash risk [e.g.,
sample surveys, laboratory experiments, and epidemiological
studies like case-control and their variant, “culpability” studies (2,
7)]. Each of the study approaches has strengths and weaknesses.
For instance, it is challenging in epidemiological studies to
obtain the proportion of cannabis users in their samples. Some
studies rely on self-reports which may underestimate the actual
fraction of cannabis users. Only a minority of all studies assesses
cannabis content in blood or other body tissues or fluids at
the time of the crash. However, it may be unclear whether the
cannabis consumption is occasional or frequent, or when the
last cannabis intake occurred prior to the crash. Among other
factors which may contribute to crash risk under the influence
of cannabis are the use of additional substances (e.g., alcohol)
and the frequency and chronicity of cannabis use. Again, only
a fraction of studies reports a combined assessment of various
legal and illicit substances or controls for other confounding
factors (7).
Timing of cannabis use prior to an event and frequency
of cannabis use have different effects on driving skills. While
laboratory and experimental studies are often of small sample
size, they usually assess specific driving impairment under
various but defined doses of smoked or oral cannabis products (6)
in an artificial environment with participants themselves aware of
possible impairments from cannabis use who tried to compensate
with slower and less risky driving (6).
These laboratory investigations are complemented by a recent
double-blind, randomized clinical trial on n = 26 healthy
occasional cannabis users (9) which were exposed to vaporized
THC-dominant, CBD-dominant, THC/CBD-equivalent, and
placebo cannabis. The end point measured was standard
deviation of lateral position (SDLP; a measure of lane weaving)
during 100 km on-road driving tests 40 and 240 min after
cannabis consumption.
The SDLP following vaporized THC-dominant and
THC/CBD-equivalent cannabis vs. placebo was shown to
be significantly greater at 40–100 min but not 240–300 min,
but there were no significant differences between CBDdominant cannabis and placebo. The doses tested here may be
representative of common usage.
In comparison, epidemiological and survey samples are
frequently not assessed regarding their neuropsychological
impairments which may lead to heterogeneity of study results.
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Not surprisingly, some studies which analyzed the association
between use of cannabis and the risk of car vehicle crashes
reported an increased risk (10–12), while others reached
inconclusive results (13, 14).
Different study types have various outcome criteria. Some of
the meta-analytical studies included crashes with injuries and
fatalities (2) while others included simple collisions (6, 15), all
of which have a different profile of risk factors. Also, five metaanalyses summarized the effect size of DUIC (2, 6, 15–17) and
suggested that the risk of vehicle crashes is increased by cannabis.
All studies used a random-effect model to assess the effect size of
cannabis use on car crashes. However, all studies also reported
a significant heterogeneity across analyzed studies. The more
recent meta-analysis reported that the significant heterogeneity
found was caused by publication bias favoring studies showing a
positive association between DUIC and car crash risk (15).
In summary, one study approach alone may be insufficient to
assess driving skills and traffic offenses in DUIC due to a variety
of confounding and methodological factors.

RESEARCH QUESTIONS
This review has three purposes. First, we searched the scientific
evidence for a link between the use of cannabis, driving safety,
and risk of car crashes by concentrating on recent meta-analyses
and large case-control-studies. Second, we evaluated the role
of sample subgroups (e.g., role of co-consumed alcohol), study
types (e.g., case control vs. culpability), and kind of crash
(collision, injury, fatality) regarding DUIC and car crash risk.
Third, independent of meta-analyses, we wanted to clarify the
relationship between car crashes and different concentrations of
THC detected in blood or other body fluids of drivers.

METHOD
This review is part of an expert report [Cannabis: Potential
and Risks: A scientific analysis (CaPRis)] funded by the
German Ministry of Health (18). It followed guidance of the
Cochrane Collaboration (19). Other parts of this report have
been published earlier (20). The study protocol can be found
at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?
ID=CRD42016033249.

Rationale
In accordance with the German Association of the Scientific
Medical Societies (AWMF) (21) this review followed a top-down
search strategy. We prioritized studies with the highest level of
evidence, i.e., aggregated data in systematic reviews and metaanalyses according to PRISMA (22). If our first search failed to
answer the clinical questions, we then included studies with a
lower level of evidence (e.g., cohort studies, case control studies).
PubMed, PsycINFO, Medline, Embase, and the Cochrane Library
were systematically searched. References of the identified reviews
and meta-analyses were manually searched to identify additional
studies. Researchers in this field were contacted. Screening of
the search results, assessing eligibility and methodological quality
of full-text articles, data extraction, and data synthesis were
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independently performed by two reviewers; disagreements were
resolved through consensus or referral to a third expert.

included (26–30). According to the included study designs, the
evidence was rated 3 as “good to moderate” quality (24).

Eligibility Criteria

Results of Meta-Analyses

The inclusion criteria were systematic reviews or meta-analyses
and prospective cohort studies investigating the effects of
cannabis use on cognition, intelligence, driving performance, and
traffic crashes. All studies published in English or German from
2005 to 2020 were considered. Outcome criteria wasn’t specified.
Exclusion criteria were non-systematic reviews, reviews without
documented systematic literature search, systematic reviews
not focusing on cannabis/cannabinoids, animal and molecular
studies, expert opinion, and position statements.

Asbridge et al. (2) conducted the first meta-analysis, which we
rated as “high” for its methodological quality (“++”) according
to SIGN (23). It included four studies on traffic accidents and
injuries, and five studies on fatalities related to cannabinoid
use. The authors used the Newcastle-Ottawa-Scale (31) for
the assessment of retrieved studies. Their screenings resulted
in a “high”-rating for four and a “moderate”-rating for five
of these studies. In eight of the nine included studies, THC
was analyzed in whole blood, serum, or plasma while one
included study (10) relied on self-reported use. Seven of the nine
included studies reported significantly increased traffic crash risk
in individuals up to 1 h after cannabinoid use. Overall metaanalytical statistics demonstrated an OR of 1.92 (95% CI 1.35–
2.73, Table 1) for crashes after cannabis use and thus almost
doubled the risks compared to controls, after weighting the
studies. Hence, heterogeneity of results and research designs
across the nine studies were substantial. Studies which received
“moderate” quality rating reported a lower car crash risk
(OR of 1.78) compared to those with “high” quality ratings
(OR 2.21). Furthermore, case-control studies had significantly
higher OR for traffic crashes following cannabis use (OR =
2.79; 95% CI: 1.23–6.33) than culpability studies (OR = 1.65;
95% CI: 1.31–3.36, Table 1). Additional analyses revealed that
traffic crash risk is increased in both fatal and non-fatal cases
after cannabinoid consumption while fatal cases only achieved
statistical significance (fatal crashes OR 2.1; 95% CI 1.31–3.36 vs.
non-fatal crashes OR 1.74; 95% CI 0.88–3.46).
The meta-analysis of Li et al. (16) received an “acceptable”
(“+”) quality rating according to SIGN (23). Nine studies were
included in their analyses of which six investigated non-fatal and
one fatal car crashes while two investigated both fatal and nonfatal car crashes under the influence of cannabis. Study types
considered in this meta-analysis included case-control, crosssectional, and cohort studies. Five of the nine studies assessed
marijuana use based on self-reported data, and 2 were based on
urine, one on blood, and one on both urine and blood tests. Eight
of the nine studies reported an increased traffic crash risk after
cannabis use except for one report from Thailand (32). Results
of the meta-analysis demonstrated a statistically significant OR
of 2.66 (95% CI 2.07–3.41, Table 1) after weighting study results.
Most results stayed significant after controlling for several
confounding factors like alcohol intake, while adjusted ORs
decreased after statistical correction. However, heterogeneity of
results also achieved statistical significance. Secondary analyses
revealed that study designs, methods of drug testing, or age
of study participants influenced outcomes. It is important to
note that studies had variable approaches to assess cannabis use
before driving. While cross-sectional and case-control studies
limited cannabis use by self-report and laboratory tests between
1 and 3 h before driving, cohort studies relied on self-reports of
current and last year’s cannabis use. Further, in their analyses,
OR for several potentially confounding factors were determined.
Cross-sectional studies (two studies) had the highest crash risk

Search Strategy and Methodological
Assessment
For the global search, terms (MeSH-Terms) used were:
“Cannabis OR cannabinoid∗ OR hemp OR hanf ” OR 2)
“Mariuana OR Marihuana OR Marijuana.” Search strings were
built, pilot-tested, and adopted to different databases. All studies
included were rated for their methodological quality using
the SIGN-checklist (23) revealing scores ranging from “high
quality (++),” “acceptable quality (+),” “low quality (–),” to
“unacceptable – reject.” Each study was rated on its level of
evidence, based on study type and quality (24) ranging from “1”
(highest level of evidence) to “5” (lowest level of evidence).

Data Synthesis
This review applied a qualitative data synthesis approach. An
aggregated data analysis couldn’t be used because of the high
heterogeneity of primary outcome measures. The study results
were interpreted with respect to their sample size, level of
evidence, risk of bias, and level of heterogeneity/homogeneity.
If there was a case of duplicate primary studies, the following
preference criteria was included (23): the availability of numerical
data or results; the highest SIGN-rating (Quality assessment
tool for systematic reviews); most recent date of publication;
larger number of studies and observations. Assessments were
made independently for each outcome. If two reviews with
duplicate primary studies reported on different outcomes, both
were eligible for inclusion.

RESULTS
The global literature search identified 470 publications across
all databases. After removal of duplicates, 272 manuscripts
remained and were screened for eligibility (Figure 1). The
literature search on cannabis, driving skills, and related crash
risks resulted in 14 publications of which three were not
systematic reviews (1, 3, 6) and one report was not included for
further analyses (25) because it did not report on driving skill
characteristics. Three studies (2, 7, 15) reported meta-analytic
results on cannabis use and car accidents and were considered
for inclusion. Two subsequent studies were published after the
CAPRIS literature search (15, 17) and were also included. To
evaluate the relationship between THC blood concentrations
and crash risk, five large case-control (culpability) studies were
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FIGURE 1 | Prisma flow diagram cannabis use and car crash risk (see also Results section).

increased the risk for traffic crash up to 50% while the risk
for a fatal crash had an OR of 1.31 (95% CI 0.91–1.88,
insignificant, 1.26, 0.88–1.81 after adjusting for publication bias).
Car crashes with injuries resulted in an OR of 1.26 (95%
CI 0.99–1.6, 1.10, 0.88–1.39) while the risk for crash-related
property damage was significantly increased (OR 1.48, 95%
CI 1.28–1.72) which remained significant after controlling for
publication bias (OR 1.26, 95% CI 1.1–1.44, Table 1). Risk for
severe injuries in crashes was higher in studies with self-reported
cannabis use (OR = 1.31; 95% CI: 0.8–2.15) vs. laboratory
screenings of body fluids (OR = 1.16; 95% CI: 0.79–1.71).
In this meta-analysis, again, quality of included studies had
a significant effect on outcome ORs. A numerical index of
study quality was developed and found that studies with high
index scores sometimes reported lower estimates of risk than
studies with low index scores (12). It remains unclear which
of the studies included in the meta-analysis were of “low” and
“high” quality.
Rogeberg and Elvik (17) conducted a meta-analysis on two
study samples. The first analysis replicated previous work (2, 16),
which the authors found hard to interpret (17).

(OR 3.61), followed by case control-studies (five studies) (OR
2.63) and cohort studies (two studies, OR 2.04). Estimated
ORs of self-reports were increased in comparison to blood or
urine testing (2.93 vs. 2.26) as well as studies in subjects aged
under 25 years (3.03) vs. other age groups (2.50). Moreover,
five of the nine studies reported co-use of alcohol, but ORs are
not reported.
Elvik (7) included the largest research with 27 studies from
Europe, USA, Canada, Australia, New Zealand, and Thailand. It
received a “high” quality rating (“++”) according to SIGN (23).
Study types included were case-control (ten), culpability (nine),
epidemiological (seven), and cohort investigations (one). Twenty
studies assessed drug use in terms of the results of laboratory
analyses of blood or saliva, but it is unclear from the analyses how
many studies investigated blood or saliva or other body fluids,
like urine.
These studies had a low to moderate methodological quality
which was due to differences in controlling for potential
confounding variables. Meta-statistics estimated ORs of severity
of the crash and computed ORs separately for fatal crashes
as well as for injuries and property damage. Cannabis use
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states, including alcohol- and substance-free controls. Using
logistic regression analyses; influence of alcohol, cannabis, and
other substances; and other factors like age and gender on
likelihood of culpability were determined. Drivers with blood
THC concentrations of 5 ng/ml or higher showed greater and
more statistically significant odds ratio (OR 6.6, 95% CI 1.5–
28.0) (Table 2). The estimated odds ratio is greater than that for
drivers with a blood alcohol concentration (BAC) of 0.10–0.15%
(OR 3.7, 95% CI 1.5–9.1). A significantly positive association with
culpability was seen with drivers positive to THC and with BAC
≥ 0.05% compared to those with BAC ≥ 0.05% alone (OR 2.9,
95% CI 1.1–7.7).
The same authors recently conducted a culpability study to
include 5,000 injured motor vehicle drivers with comprehensive
blood toxicology testing (30). The sample included 1,000 drivers
for each of 5 years from ∼5,000 to 6,000 drivers injured and taken
to hospital in the State of Victoria, Australia. A comprehensive
blood-testing was conducted. In a logistic regression, drivers
under the influence of THC showed a modest increase in
culpability odds, when concentrations of all assessed substances
were considered vs. controls (OR 1.9, 95% CI 1.2–3.1, p =
0.007). The increase in odds was most obvious at higher blood
THC concentrations. At 5 ng/mL and above the OR was 3.2
(p = 0.01), and at THC concentrations of 10 ng/mL and above
the OR was 10 (p = 0.03). At 1–5 ng/ml, the OR was 1.6
(95% CI 0.9–2.7), 5–9 ng/ml 1.9 (95% CI 0.7–5.0), 5 ng/ml and
above the OR was 3.2 (95% CI 1.3–7.2, p = 0.01), and at THC
concentrations of 10 ng/mL and above the OR was 10 (95%
CI 1.3–82, P = 0.03). These results indicated increasing odds
of culpability with rising concentration. THC was the third
most prevalent drug detected in 11.1% of all drivers, following
alcohol and stimulants. Only 1% of the 5,000 drivers had THConly at 10 ng/mL or higher. The authors conclude that their
culpability analysis of almost 5,000 injured drivers provided
further evidence that elevated odds of culpability correlate
with increasing THC levels, particularly those with higher
blood concentrations.
Laumon et al. (27) conducted a case-control study on
cannabis intoxication and fatal road crashes in France. They
analyzed n = 10,748 drivers, with known drug and alcohol
concentrations, involved in fatal crashes in France from October
2001 to September 2003. A total of 6,766 of these were
considered culpable at the crash while n = 3,306 drivers served
as controls. In addition, n = 681 drivers were positive for
cannabis (cases 8.8%, controls 2.8%), including 285 with an
illegal blood alcohol-concentration (≥0.5 g/l). Positive cannabis
detection was associated with increased risk of responsibility
(OR 3.32, 95% CI 2.63–4.18). A significant dose effect was
identified; the odds ratio increased from 2.18 (1.22–3.89) for
0 < THC < 1 ng/ml to THC ≥ 5 ng/ml OR 4.72 (3.04–7.33),
uncorrected. The effect of cannabis remains significant after
adjustment for different cofactors, including alcohol, with which
no statistical interaction was observed (Table 2). At least 2.5%
(1.5–3.5%) of fatal crashes were estimated as being attributable
to cannabis, compared with 28.6% for alcohol (26.8–30.5%). The
authors concluded that driving under the influence of cannabis
increases the risk of involvement in a fatal car crash, while

After re-analysis of the Asbridge study, adjusted OR estimates
of 1.25 (95% CI 1.0–1.55) were found (from previously reported
1.95, 1.35–2.73) and for the Li et al. study, adjusted OR was ∼1.55
(95% CI 1.10–2.20, from 2.66, 2.07 to 3.41, previously reported).
In the second meta-analysis, 21 observational studies were
included. Revised estimates were in a similar range as the
adjusted ORs of study 1 (re-analyses of Asbridge et al. and Li
et al. data). A statistically significant increase in risk of lowto-moderate magnitude OR 1.36 (1.15–1.61) was reported from
the mixed model and an OR of 1.22 (1.1–1.36) in the metaregression model.
Subsample analyses found relatively higher OR estimates for
case–control studies OR 1.36 vs. culpability OR 1.12, low OR 1.45
vs. high quality OR 1.39, no limited control of confounders OR
1.52 vs. high confounder adjustment OR 1.17, and not controlling
for alcohol intoxication OR 1.79 vs. controlling OR 1.11. In
general, OR estimates of the relationships between cannabis use
and car crash risk and subgroups are somewhat lower than those
reported from previous meta-analyses (17).
Hostiuc et al. (15) employed two meta-analytical statistical
approaches of DUIC and traffic crash risk. These approaches
included a random-effects and inverse variance heterogeneity
model to assess statistical significance of effect sizes. Altogether,
n = 24 studies were included into the analyses, of which n =
10 relayed on blood analyses (one blood, urine and saliva, two
on blood and self-report, one urine and blood, one saliva and
blood combinations), n = 10 on self-report only (one additional
study on self-report and saliva), one on urine analyses and two
on “official databases.” Crash risk in DUIC tested via blood
analyses had an OR of 1.97, fatal accidents reached an OR of
1.56, and self-reports an OR of 1.94, while the overall effect size
for DUIC and crash risk was not statistically significant. Across
study types, again, case-control studies presented a higher OR
(1.99) than other study types (1.81). Moreover, risk of crashes
with injury (OR 2.18) in DUIC and collision (OR 1.81) were
higher than those for fatal car crashes (OR 1.73). Using the
alternative statistical model, OR estimates were generally 0.2
lower (Table 1). The authors considered several possible causes
for their results in the meta-analysis, including heterogeneity
of study types and assessment methods. Indeed, no association
between DUIC and crash risk and a lack of sensitivity of
their statistical approach (random effects model) was found. In
addition, publication bias was remarkably high, but rather toward
studies reporting a positive association between DUIC and crash
risk. To homogenize and focus research on this topic, the authors
suggested corroboration with objective data on cannabis use (like
blood analyses, with clear cut-off values), or a clinical assessment
of the impairment, in the event of a positive screening in traffic,
before assessing the individual’s fitness to drive (15).

Relationship Between Different THC Blood
Concentrations and Car Vehicle Crashes
Five large case-control studies (26–30) assessed the link between
THC blood concentration and crash risk.
Drummer et al. (26) investigated n = 3,398 fatal crashes
under the influence of alcohol and drugs from three Australian
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TABLE 1 | Meta-analyses of driving under the influence of cannabis (DUIC) and risks of car vehicle crash studies.
References

N participants

N studies

Hostiuc et al. (15)

n = 245,591

24 studies

Odds ratio selected outcomes

95% CI

REM:

++

All: 1.89

1.58–2.26

Collision: 1.95

1.24–3.05

Injury: 2.16

1.41–3.28

Fatal: 1.73

1.36–2.19

Case-control: 1.95

1.51–2.51

Other studies: 1.81

1.38–2.39

REM

Rogeberg and Elvik (17)
n = 50,877 +

+

9 + 9 studies

All: 1.36

1.15–1.61

n = 93,229

21 studies

Fatal 1.32

1.08–1.62

n = 239,739

(re-analysis)

Case Control 1.60

1.19–2.15

27 studies

REM

Elvik (7)

++

Property damage: 1.26

Li et al. (16)

n = 93,200

9 studies

1.10–1.44

Injury: 1.10

0.88–1.39

Fatal 1.26

0.88–1.81

Self-report:1.31

0.80–2.15

Lab Tests: 1.16

0.79–1.71

REM

+

All: 2.66

Asbridge et al. (2)

n = 51,783

9 studies

SIGN

2.07–3.41

Case-control: 2.63

1.87–3.71

Cohort: 2.04

1.36–3.07

Cross-sectional: 3.61

2.37–5.49

Self-report: 2.93

2.07–4.17

Blood/urine test: 2.26

1.46–3.49

REM

++

All: 1.92

1.35–2.73

Case-control: 2.79

1.23–6.33

Culpability: 1.65

1.11–2.46

Fatal: 2.10

1.31–3.36

Non-fatal: 1.74

0.88–3.46

CI, confidence interval; SIGN Methology Checklist: High quality (++), acceptable (+), unacceptable (–), reject (0); REM, random effects model.

Brubacher et al. (29) recently conducted a responsibility
analysis in a case-control sample to determine whether drivers
injured in motor vehicle collisions who tested positive for THC
or other drugs are more likely to have contributed to the crash
than those who tested negative. Participants included n = 2,318
injured drivers who required blood tests for clinical purposes
following a motor vehicle collision, of whom 8.3% were screened
positively for THC and 14.4% for alcohol. In addition, excess
whole blood remaining after clinical use was obtained and
broad-spectrum toxicology testing performed. To analyze data,
unconditional logistic regression to determine ORs of crash
risk for drivers with 0 < THC < 2 ng/ml, 2 ng/ml ≤ THC <
5 ng/ml and THC ≥ 5 ng/ml (all vs. THC = 0 ng/ml). Risk
estimates were adjusted for age, gender, and presence of other
impairing substances. Odds ratios for all three ranges of blood
tested THC were low (Table 2) and not statistically significant.
Alcohol × Cannabis interactions were detected for pos. BAC
× THC < 2 ng/ml OR = 1.75 (0.37, 17.1) and × THC ≥
2 ng/ml OR = 1.62 (0.34, 15.7) which did not reach statistical

the risk in their study was lower than that with positive blood
alcohol concentrations.
Martin et al. (28) conducted a similar French cohort study
more than a decade later. The authors included n = 4,059 drivers.
More than 300 of their characteristics, including DUIC and fatal
crash risk, were obtained. The proportion of persons driving
under the influence of alcohol was 2.1% (95% CI: 1.4 ± 2.8) and
under the influence of cannabis 3.4% (2.9–3.9%). Drivers under
the influence of cannabis multiplied their risk for causing a fatal
crash by 1.65 (1.16 ± 2.34). Strength of the study is certainly its
presentation of separate crash ORs for various doses of cannabis
detected in blood samples, after adjusting for age, gender, vehicle
category, and time of crash, which replicated results from a
previous publication of the same research group (27) and the
Australian study (26) (Table 2). Another finding of the second
French sample is that there was no significant alcohol × cannabis
interaction. This means that the increased risk of a fatal crash
due to alcohol does not differ significantly from driving under
the influence of cannabis (and vice versa).
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TABLE 2 | Case control studies of fatal traffic injuries dividing drivers into culpable (or responsible) cases and non-culpable cases.
Odds ratio† ; * - ****

References

Country

N

THC in blood ng/ml

Drummer et al. (30)

Australia

5,000 drivers injured as a
result of a vehicular collision

THC (all concentrations)
THC 1–4.9
THC 5–9.9

1.9****

0.7–5.0

THC ≥ 5

3.2****

1.3–7.2

THC ≥ 10

10****

1.3–8.2

Brubacher et al. (29)

Martin et al. (28)

Laumon et al. (27)

Drummer et al. (26)

Canada

France

France

Australia

2,318 non-fatally injured
motor vehicle drivers

4,059 fatal accidents

10,748 fatal traffic crashes
while driving under the
influence of cannabis

3,398 fatal accidents

THC = none detected
0 < THC < 2

Confidence
interval

SIGN****

Body tissue or
fluid analyzed

1.9****

1.2–3.1

++

“Blood samples”

1.6****

0.9–2.7

++

“Whole blood
samples”

++

“Blood
concentration of
THC of over 1
ng/ml”

++

“Blood
concentration of
THC of over 1
ng/ml”

++

Blood (post
mortem)

Reference
1.09***

0.63–1.92

2 ≤ THC < 5

1.16***

0.66–2.13

THC ≥ 5

1.74***

0.59–6.36

Any THC

1.13

Any (≥1)
THC < 1

1.65**
1**

1.2–2.3

THC 1–3

1.4**

0.9–2.1

THC 3–5

3.6**

1.4–9.5

THC ≥ 5

1.6**

0.9–3.0

Any
THC < 1

Reference
1.6*

1.4–2.3
0.8–3.0

THC 1–2

1.5*

1.1–2.2

THC 3–4

2.1*

1.2–3.7

THC ≥ 5

2.1*

1.3–3.4

Any dose

1.78*

1.4–2.3

Any THC

2.7

1.02–7.0

THC ≥ 5

6.6

1.5–28.0

†

1.03–1.28

*Included variables: blood concentration of delta-9-THC, blood concentration of alcohol, age, vehicle type, time of crash.
**Included variables: age, gender, vehicle category, time of accident.
†
***Logistic regression with adjustment for age, sex, health authority, cannabis, alcohol, other recreational drugs, and sedating medications. Unadjusted model.
****Logistic regression with adjustment for gender, age group, type of vehicle (car/motorbike/heavy vehicle/van or light truck) and location (metro/rural).
SIGN Mythology Checklist: High quality (++), acceptable (+), unacceptable (–), reject (0).

studies with n = 51,783 participants, the second meta-analysis
from the same year (16) also included nine studies with n =
92,200 individuals. In this second meta-analysis (16), only two
studies (9, 31) were previously analyzed (2). The third metaanalysis (7) with 27 studies included eight studies each of the
first (2) and second (16) meta-analysis, while 12 studies were
added. Rogeberg and Elvik (17) re-analyzed data from the first
and second meta-analysis (2, 16) and added a second study
with 21 included investigations, of which n = 14 were also
analyzed in the previous study of Elvik (7). The most recent
analysis (15) included 24 studies, of which 12 were analyzed
in the hitherto largest meta-study (7). Thus, there is some,
but not complete, overlap of studies included into available
meta-analytical research on this topic. Selection criteria also
vary across studies. Some include case-control and culpability
studies (2, 17) or in addition cohort (16) or laboratory studies
(7) and eventually case-control, culpability, survey, and cohort
studies (15).
All meta-analyses noted significant heterogeneity across
included studies [Asbridge et al. (2): I2: 81; Li et al. (15):
heterogeneity: Q = 38.21; P < 0.0001; I2 ¼ 79.1; Elvik (7):
test for heterogeneity “positive” for all outcomes; Rogeberg and
Elvik (17): “there is heterogeneity across studies;” Hostiuc et al.

significance. Unadjusted OR for car crash risk under any THC
blood level was 1.13 (1.03–1.28). This study, like other culpability
and case control studies, relied on blood samples instead of
self-reports. Additional strengths are the assessment of alcohol
and recreational drug use. However, in comparison to the three
previous case-control/culpability studies which included fatal
crashes, non-fatal motor crashes with injuries only were analyzed
in this study (29).

DISCUSSION
In this review we first analyzed the general relationship between
any crashes in DUIC chronic cannabinoid use, and second,
how this relationship changes when potential co-factors are
considered. The research on these topics includes five metaanalyses on several study types (case-control, culpability, and
cohort studies) (2, 7, 15–17).
All five meta-analyses agreed that cannabinoid use is related
to a higher traffic crash risk. However, the OR estimates and
95% CI and statistical significance across studies are variable
(Table 1), while the number of included studies unsurprisingly
increase over time. The initial meta-analysis (2) analyzed nine
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(2), Elvik 20 of 27 (7), Li et al. 2 of 9 (16), and Hostiuc et al.
10 of 24 studies (15)]. All of these limit the generalizability
of findings.
In addition, whole blood, plasma, urine, and saliva are body
fluids with different characteristics when it comes to assessment
of THC levels. Experimental studies could not find a significant
correlation between THC concentrations (logarithms) in oral
fluid and plasma, while time influences THC concentrations
in plasma and oral fluid differently after repeated oral THC
doses (33). Cannabinoids in urine have a longer window of
detection than blood and oral fluids, and THC’s elimination
is non-linear so that reverse extrapolation of concentrations
to an earlier time is not feasible. When utilizing blood rather
than plasma cannabinoid concentrations, concentrations must be
approximately doubled because cannabinoids are tightly bound
to proteins in plasma (>90%), and there is minimal partitioning
into erythrocytes (34).
Also, cannabinoid blood and plasma concentrations were
significantly higher in frequent smokers compared with
occasional smokers at most time points for THC and 11-OHTHC (35). In oral fluids, THC levels above 2 µg/L were detected
in occasional smokers for 26 h while frequent smokers had higher
levels for >72 h. Thus, low THC concentrations can be detected
for several days in oral fluids of chronic smokers similar to blood
and urine (36). Eventually, the authors of the review comment
that cannabinoid stability in these measures not only depend on
characteristics of the body fluids used and the smoking status
of the individuals, it also depends on collection method, buffer
composition in commercial collection devices, the analytes,
storage containers, and storage temperature and duration.
The third purpose of our analyses on the relationship between
THC concentration and car crash risk was addressed by five casecontrol studies with “high quality (++)” SIGN rating (Table 2).
None of the meta-analyses reported statistics on this relationship.
However, the association is of importance since there are various
legal cut-off values for THC blood levels across European
countries for DUIC. While the penalty increases in Norway
according to the THC concentration detected (1.3, 3, 9 ng/ml),
other countries have cut-off values of 1 ng/ml (Germany,
Belgium, Ireland, Luxemburg, Netherlands in the presence of
other substances), 2 ng/ml (Czech Republic, United Kingdom),
and 3 ng/ml (Netherlands) [EMCDDA Cannabis and Driving
(5)]. It is a relevant issue whether studies report evidence
using which of the legal cut-off concentrations supported by
empirical data.
The Australian study (26) indicated a significantly higher
risk for THC ≥ 5 ng/ml with the highest OR estimates across
studies (OR 6.6) which is higher than ORs from later studies
[Laumon et al. (27) unadjusted OR (uaOR) 4.7, Martin et al. (28)
(uaOR) 3.95, and Brubacher et al. (29) (uaOR) 2.29 for the same
subgroup of individuals with THC ≥ 5 ng/ml]. However, in the
Drummer et al. sample, in 84% of the THC-only cases the THC
concentration was ≥5 ng/ml and the median was 12 ng/ml. This
rate is higher compared to the French and Canadian samples
[Laumon et al. (27): 2.66%, Martin et al. (28): 4.2%, Brubacher
et al. (29): 0.9%]. Therefore, based on the high rate of individuals
with THC above 5 ng/ml, it was quite likely to see an effect of

(15): overall Q = 216,59, p < 0.001; I2 = 90%]. The last
study also presented heterogeneity statistics for several outcome
criteria [collision subgroup Q = 47,06, p < 0.001, I2 89%; injury
subgroup Q = 62.0; p < 0.001, I2 82%; fatal Q = 19.26, p < 0.001,
I2 79% (15)].
All these factors may explain why there is some variation in
the OR estimates across meta-analyses for the overall statistics.
Further, case-control studies reach higher OR estimates than
culpability studies and, except for (2), fatal crashes lower OR
estimates than other kinds of crashes. Finally, studies based
on self-reports have higher ORs than those based on blood or
urine results. Culpability studies (2) include drivers involved in
collisions, sub-grouped into those responsible for the collision
and those not responsible. The premise of these studies is, if
cannabis use increases collision risk, then it should more likely
be detected in drivers judged to be responsible for their collision.
However, OR may be higher in case-control studies, where DUIC
subjects are compared to non-DUIC controls. Further, DUIC
may impair driving skills and increase crash risk, however, risk
of fatal crashes is lower than other types of crashes (collision
only, injury). Thus, the increased risk for car crashes is relatively
higher for collision and injury and somewhat attenuated but still
increased for fatalities.
Self-reports of cannabis use may be subject to recall bias and
may be less precise to detect actual cannabis use compared to
blood or urine tests. Usually, it is assumed that cannabis use
is underestimated in self-reports. As commented in previous
analyses (16) different methods of assessing cannabis use (e.g.,
self-report, urine tests, and blood tests) may have different levels
of validity and reliability. The authors of one meta-analysis (17)
stated that, to their view, laboratory analyses of blood samples
for all subjects included in a study provide the best information
on acute intoxication while driving. The second best indicator
is saliva. Urine is a less informative indica tor, as inactive
metabolites of cannabis can be detected in samples of urine a long
time after the substance became inactive.
Most of these screenings determine whether cannabis was
used within the past few weeks, whereas acute impairment in
driving skills from cannabis use lasts between 3 and 12 h (16, 33).
Cannabis being an illicit drug in most countries, drivers in the
comparison groups might be less likely than those involved in
crashes to submit to testing, which could lead to overestimation
of the effect of marijuana use on crash risk.
These meta-analyses have several limitations. The fourth
meta-analysis (17) found only five studies that calculated crash
risk for drivers with blood THC > 2 ng/ml. Further, all case–
control studies had high refusal rates (>15%), potentially
resulting in selection bias if drivers who refused participation
had different rates of drug use than those who participated.
Different methods to detect cannabis exposure in cases vs.
controls (e.g., blood THC in cases and saliva THC in controls)
were employed in many case-control studies, non-comparable
controls (e.g., patients visiting hospital for medical problems)
were recruited to estimate THC use in the general driving
population (29), and only a fraction of included studies measured
THC in blood samples or a combination of blood samples and
urine or saliva samples or self-reports [Asbridge et al. 9 of 10
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Metabolites such as THC-COOH are present and detectable
for a significant time after consumption but lack any proven
psychoactive effects which impair driving ability.
The results of culpability and case-control studies must
be compared with findings from experimental and laboratory
studies. Laboratory and simulator studies certainly suffer
from the limitation that they are conducted in an artificial
environment. Thus, experimental data show that drivers attempt
to compensate cannabis intoxication by slower driving after
smoking cannabis, but their control deteriorates with increasing
task complexity (5, 6). These behaviors limit the generalizability
of experimental study results to authentic traffic situations (2).
However, as with other cognitive tasks, cannabis smoking (THCdominant and THC-CBD-equivalent) increases lane weaving
after 40–100 min following vaporization (9) and impaired
cognitive function consistently as well as critical-tracking
tasks, reaction times, divided-attention tasks, and lane-position
variability, all of which may increase car crash risk.
In general, however, there is no clear overall relationship
with THC blood or serum levels and driving skills or crash risk
from experimental studies, even if time of use and duration
of consumption are considered. Not surprisingly, there is no
unanimous agreement on potential THC legal cut-off levels
despite the dose effect with higher THC blood concentrations
resulting in higher OR estimates for crashes. However, a
relationship does not necessarily provide a clue for a scientifically
supported cut-off value. Experts suggest that many drivers with
blood THC >3 ng/ml (42) or >3–5 ng/ml (43) have significant
impairment and should be prohibited from driving. Based on
these reports, many jurisdictions, including many US states and
Canada, have set THC per se limits of 2 or 5 ng/ml, while many
European countries have a limit of 1 ng/ml. Advocates of these
lower THC concentrations argue that THC concentration drops
rapidly after smoking, so a driver impaired with high THC
concentrations at the time of driving could show concentrations
below 5 ng/ml several hours later if there is a delay in obtaining
blood samples (44), a fact that supports lower per se limits for
THC (30). These concentrations, especially the 1 or 2 ng/ml
levels, were criticized because they may not indicate impairment
especially in frequent users who develop tolerance to some
THC impairing effects (6, 42). Due to the accumulation of
cannabinoids in fat, some daily users may have blood THC >
1 ng/ml after a week or more of abstinence (6). Therefore, the
various THC concentrations used to define a cannabis-related
driving offense in EU countries and some US-states varying
between 1 and up to 7 ng/ml alone may not be appropriate to
evaluate driving skill impairment comprehensively.
Measures of THC and its non-psychoactive metabolite THCCOOH within hours of an accident suffer from several limitations
and may not reflect driving skill impairment. Even higher
THC concentrations of >5 ng/ml in recent studies yielded
higher risks of injuries and fatal concentrations, however not
all studies reported statistically significant relationships. Rather,
the assessment of both biological measures and psychomotor
characteristics may render evaluation of driving fitness more
accurate (more valid to “real” impairment) and is probably
applicable in practical traffic control situations. Thus, future

THC on crash risk in the Australian sample. Further, in the
Australian study (26), alcohol was commonly found in THCpositive cases (43%), the effect of THC was also evaluated in the
THC plus alcohol cases and significant interaction was found.
This interaction could not be replicated in French and Canadian
samples. In the first French study (27), no statistical interaction
between blood concentrations of THC and alcohol was detected
as well as in the later studies (28, 29). Thus, most studies report
a significant influence of cannabis and alcohol use on culpability
for fatal crashes or injuries, but both substances obviously exert
their effects independently (6). Results from the Australian Study
(26) also suggested that both alcohol and cannabis showed a
biological gradient with higher doses of both substances have a
higher OR of culpability in fatal crashes. This significant doseeffect was also reported from the first French (27) and the
Canadian Study (29), while in the second French study (28), the
ORs show an inverse U-curve trend with a maximum at THC
concentrations between >2 and <5 ng/ml, after controlling for
alcohol intoxication. All authors across studies consistently argue
that their studies yield a marked dose effect and a potential causal
role of DUIC in fatal crashes. The latest study of Drummer et al.
(30) confirmed the finding that elevated odds of culpability are
positively associated with THC, particularly those with higher
blood concentrations.
Culpability studies may be well suited to compare risk of fatal
and non-fatal crashes, because THC blood levels were measured
in all five samples. If THC blood levels are compared regarding
fatal (26–28) and non-fatal crashes (29, 30), the odds ratios for
any THC blood levels are similar [fatal crashes: 2.7 ng/ml (26),
1.78 ng/ml (27), 1.65 ng/ml (28) vs. non-fatal crashes 1.13 ng/ml
(29), 1.9 ng/ml (30)] while the levels in fatal crashes tended to be
higher. A previous meta-analysis and systematic review, which
excluded low-quality studies, reported cannabis-associated risk
for non-fatal crashes (OR = 1.74; 95% CI = 0.88–3.46) and for
fatal crashes (OR = 2.1; 95% CI = 1.31–3.36) (2) and confirm the
findings for the included five culpability studies in our analysis.
However, case-control and culpability studies have
limitations. As several of the authors pointed out, estimating
the degree of intoxication for cannabis is a more difficult task
than for alcohol (26, 29). As far as cannabis is concerned,
after smoking and vaporization, there is a delay in maximal
cannabis effects compared to the peak THC blood concentration
after consumption, with peak effects after ∼30 min depending
upon study design and time of testing. Effects on cognition
and psychomotor function do not decline as quickly as THC
concentration decreases (37–40). When smoking a “joint,” whole
blood THC concentrations typically peak at >100 ng/ml during
smoking and then drop so rapidly that THC is usually <2 ng/ml
within 4 h of a single acute exposure (38). Psychotropic effects
typically peak at 20–30 min and resolve by 4 h. Ingesting cannabis
delays the onset and extends the duration of these effects. The
main THC metabolite, 11-nor-9-carboxy-THC (THC-COOH),
is not psychoactive and persists in blood and urine long after
impairment resolves. Thus, THC-COOH provides evidence of
previous cannabis exposure but does not necessarily indicate
impairment or recent use (41). The active ingredient behind
most of the effects of cannabis that impair driving ability is THC.
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may be not appropriate to assess fitness to drive and should be
combined with ratings of psychomotor and cognitive skills.

experimental and laboratory research on cannabinoid’s effects
on fitness to drive should consider designs which include
measures of psychomotor and cognitive functions like reaction
times and decision making after long and monotonous drives
and divided attention tasks. These cognitive characteristics
may be most impaired by cannabis according to available
research (5, 6).
Finally, it is important to recognize that an important
compound of cannabis-products used is Cannabidiol (CBD).
As for driving skills, it is a substance with sedative effects and
therefore may play a role in impairing driving abilities and
increase risks for accidents. However, no study investigates the
influence of CBD alone on car crash risks. Certainly, since CBD
is in increasing demand in sales and consumption, further studies
are needed to evaluate the relationship between CBD use, driving
ability, and car crash risks.
In summary, there is unanimous agreement across studies
that acute cannabis use significantly increases the risk for car
crashes and impairs specific driving skills, and confidence in the
results from several types of studies (case-control, culpability, and
cohorts) is rated “moderate” according to CERQual. In metaanalyses, cannabis user’s ORs for car crashes are slightly but
significantly increased, when several confounders are considered
in multivariate analyses. Further, self-report vs. blood test, case
control vs. culpability, and non-fatal crashes had higher OR
estimates. High quality culpability studies (SIGN) noted that
there is a dose effect of higher THC blood concentrations with
increased risk for fatal crashes and those with injuries. However,
this biological gradient does not provide a clear legal cut off value.
Therefore, these cut off values still range between 1 and 5 ng/ml.
While there are various problems related to the measure of THC
and its metabolite THC-COOH in blood and other tissues within
hours after a crash (different body fluids with different time
frames of THC levels), these values may not even reflect actual
driving skill impairment. Thus, the biological measures alone
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